Review of NICE Technology Appraisal Guidance Nos 103 (part) / 134/ 146/ 180; Etanercept for the treatment of adults with psoriasis, Infliximab for the treatment of psoriasis, Adalimumab for the treatment of psoriasis and Ustekinumab for the treatment of adults with moderate to severe psoriasis

As you may be aware the planned date for review of the above guidance was early 2010.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full update of the guidance.

Having re-run the search strategy from the original assessment the Institute has not found any relevant additions to the evidence base that would have a material effect on each piece of guidance. Consequently we propose that the guidance will remain in place and be incorporated, verbatim, within the ongoing clinical guideline on the diagnosis and management of psoriasis in young people and adults.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted.

August 2010